Last reviewed · How we verify

Femoral Nerve Block Bupivacaine

The New England Baptist Hospital · Phase 3 active Small molecule

Femoral Nerve Block Bupivacaine is a Local anesthetic Small molecule drug developed by The New England Baptist Hospital. It is currently in Phase 3 development for Regional anesthesia for femoral nerve block in surgical procedures, Postoperative pain management in lower extremity surgery. Also known as: Bupivacaine.

Bupivacaine blocks sodium channels in nerve fibers, preventing the generation and propagation of action potentials to produce local anesthesia in the femoral nerve distribution.

Bupivacaine blocks sodium channels in nerve fibers, preventing the generation and propagation of action potentials to produce local anesthesia in the femoral nerve distribution. Used for Regional anesthesia for femoral nerve block in surgical procedures, Postoperative pain management in lower extremity surgery.

At a glance

Generic nameFemoral Nerve Block Bupivacaine
Also known asBupivacaine
SponsorThe New England Baptist Hospital
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia / Pain Management
PhasePhase 3

Mechanism of action

Bupivacaine is a long-acting local anesthetic that reversibly inhibits sodium influx through voltage-gated sodium channels in nerve cell membranes. When administered as a femoral nerve block, it diffuses into nearby nerve tissue and prevents depolarization, thereby blocking sensory and motor nerve conduction in the femoral nerve territory. This produces regional anesthesia and analgesia for surgical procedures and pain management in the lower extremity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Femoral Nerve Block Bupivacaine

What is Femoral Nerve Block Bupivacaine?

Femoral Nerve Block Bupivacaine is a Local anesthetic drug developed by The New England Baptist Hospital, indicated for Regional anesthesia for femoral nerve block in surgical procedures, Postoperative pain management in lower extremity surgery.

How does Femoral Nerve Block Bupivacaine work?

Bupivacaine blocks sodium channels in nerve fibers, preventing the generation and propagation of action potentials to produce local anesthesia in the femoral nerve distribution.

What is Femoral Nerve Block Bupivacaine used for?

Femoral Nerve Block Bupivacaine is indicated for Regional anesthesia for femoral nerve block in surgical procedures, Postoperative pain management in lower extremity surgery.

Who makes Femoral Nerve Block Bupivacaine?

Femoral Nerve Block Bupivacaine is developed by The New England Baptist Hospital (see full The New England Baptist Hospital pipeline at /company/the-new-england-baptist-hospital).

Is Femoral Nerve Block Bupivacaine also known as anything else?

Femoral Nerve Block Bupivacaine is also known as Bupivacaine.

What drug class is Femoral Nerve Block Bupivacaine in?

Femoral Nerve Block Bupivacaine belongs to the Local anesthetic class. See all Local anesthetic drugs at /class/local-anesthetic.

What development phase is Femoral Nerve Block Bupivacaine in?

Femoral Nerve Block Bupivacaine is in Phase 3.

What are the side effects of Femoral Nerve Block Bupivacaine?

Common side effects of Femoral Nerve Block Bupivacaine include Systemic toxicity (CNS effects: tremor, seizure), Cardiovascular effects (hypotension, arrhythmia), Local tissue irritation or hematoma at injection site, Nerve injury or paresthesia.

What does Femoral Nerve Block Bupivacaine target?

Femoral Nerve Block Bupivacaine targets Voltage-gated sodium channels and is a Local anesthetic.

Related